On September 9, 2026 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, reported two poster presentations at the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, which will be held September 9-12 in Houston, Texas.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PharmaEssentia will present two-year results from the Phase 3 SURPASS-ET study (NCT04285086) and its ongoing extension in adults with high-risk essential thrombocythemia (ET) who were resistant to or intolerant of hydroxyurea. In the extension, it was observed that study participants who continued BESREMi (ropeginterferon alfa-2b-njft) maintained modified ELN response rates and platelet and white blood cell control through two years, with continued reduction in JAK2V617F variant allele burden and a safety profile consistent with prior reports. Patients followed in the extension study who transitioned from anagrelide to BESREMi after the 52-week core study showed improved hematologic control and reduced JAK2V617F allele burden relative to their prior anagrelide therapy. Long-term efficacy and safety analyses are ongoing. Two-year results were presented in part as an oral presentation at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress.
Additionally, PharmaEssentia will present real-world evidence from a retrospective cohort study of 55 patients with ET evaluating the use of BESREMi in community oncology settings. The analysis found that BESREMi was most commonly initiated after first-line therapy, while first-line use was also observed, predominantly in younger patients. Platelet counts and response rates trended toward optimal levels regardless of prior cytoreductive therapy history.
Poster Presentation Details
Title: Efficacy and Molecular Dynamics of Ropeginterferon Alfa-2b in High-risk Essential Thrombocythemia: Two-year Results from the Phase 3 SURPASS-ET Trial
Abstract Number: 944
Poster Number: MPN-944
Presenter: Dr. Lucia Masarova, University of Texas MD Anderson Cancer Center
Date: 9/9/26
Time: 6:25-7:55 PM
Title: Real-world Patient Characteristics, Treatment Patterns and Blood Counts of Patients with Essential Thrombocythemia Treated with Ropeginterferon Alfa-2b in the US Community Oncology Setting
Abstract Number: 1090
Poster Number: MPN-1090
Presenter: Dr. Solly Chedid, Singing River Cancer Center
Date: 9/9/26
Time: 6:25-7:55 PM
(Press release, PharmaEssentia, SEP 9, 2026, View Source [SID1234670697])